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Abstract
Background: There is increasing evidence that exposure to moulds (fungi) may influence the development of
sarcoidosis. To assess the influence of the environmental exposure, a study was undertaken to determine the
exposure to fungi in homes of subjects with sarcoidosis.
Methods: Subjects were patients with clinically established sarcoidosis recruited during the period September 2007
till June 2010. Of these 55 were newly diagnosed and currently under treatment for less than one year, 25 had
been treated and had no recurrence and 27 had been treated but had recurrence of the disease. Controls were
healthy subjects without any respiratory symptoms (n = 30). Samples of air (about 2.5 m
3) were taken in the
bedroom of the subjects using a portable pump and cellulose ester filters. The filters were analysed for the content
of the enzyme N-acetylhexosaminidase (NAHA) as a marker of fungal cell biomass, using a specific substrate and a
fluorescent technique and expressed as NAHA units (U)/m
3.
Results: Compared to controls, subjects undergoing treatment of the disease (newly diagnosed or with
recurrence) had significantly higher activities of NAHA in their homes than controls (33.6 and 39.9 vs 10.0 U/m
3,
p < 0.001 and <0.001). Among controls only 5 out of 30 subjects had levels of NAHA above the second quartile value
(14 U/m
3). In homes of subjects with newly diagnosed disease with treatment less than one year, values above 14
NAHA U/m
3 were found among 35 out of 55 and among those with recurrent disease among 18 out of 27.
Conclusions: The higher activities of NAHA enzyme found in homes of subjects with active and recurrent
sarcoidosis suggest that exposure to fungi is related to the risk of sarcoidosis. Further environmental studies to
assess the importance of this exposure for subjects with sarcoidosis are warranted. The results suggest that
remedial actions in homes with high levels of fungi may be justified.
Background
It has been suggested that environmental agents, parti-
cularly microbes, influence the risk to develop sarcoido-
sis [1], Epidemiological studies have shown relationships
between sarcoidosis and environments where mould
(fungi) would be present. Occupational risk factors were
evaluated among 273 cases of sarcoidosis and 618 sib-
lings without the disease [2]. Specific risk exposures that
i m p l yp o s s i b l ef u n g a le x p o s u r e sw e r ev e g e t a b l ed u s t s ,
and indoor exposure to high humidity, water damage or
musty odours. In a case-control study on 706 newly
recruited cases of sarcoidosis and equal numbers of
age-, race-, and gender matched controls, there were
positive associations between sarcoidosis and agricul-
tural employment, and work environments with mould/
mildew exposure [3]. It has also been reported that sar-
coidosis developed among subjects in a group of persons
working in a building with severe mould problems [4].
An increase risk for sarcoidosis has also been found
among fire-fighters [5,6]. They work in an environment
with high levels of aerosolized organic, humidity laden
materials.
These findings indicate that fungi in the environment
could play a role in the development of the disease.
This possible relationship does not necessarily imply
infection but could also be the results of an immune
reaction to one or several agents in the fungal cell wall.
A possible mechanism could be the development of a
late hypersensitivity reaction towards some agent in the
fungal cell wall such as b-glucan or chitin [7]. b-glucan
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could induce a pathway of sensitisation to other agents
in the fungal cell wall or agents present elsewhere.
If fungi were to play a role for the development of sar-
coidosis, one would expect that there are gradients in
the environmental exposure between those with the dis-
ease and healthy controls. To test this hypothesis, a
study was undertaken with the aim to determine air-
borne levels of fungi in homes of subjects with sarcoido-
sis and those without pulmonary disease. The presence
of fungal cells was determined by analysing the air sam-
ples for the enzyme N-acetylhexosaminidase (NAHA) as
a marker of fungal cell biomass [9].
Methods
Subjects
The clinic of respiratory diseases and allergy at the Uni-
versity medical centre, Ljubljana, Slovenia is one of the
national centres for patients with sarcoidosis. For the
diagnosis the ERS/ATS criteria [10] are used, compris-
ing a bronchial lung lavage (BAL) and one or more
transbronchial biopsies. The routine at the clinic is to
make once bronchoscopy with 5 to 10 transbronchial
biopsies and BAL with 200 mL. The presence of non-
caseating granulomas is verified histologically. If a
biopsy is not considered representative, the patient
undergoes surgical pulmonary or lymph node biopsy.
Aspiration is performed from one lobe for microbiolo-
gical analysis of bacteria, fungi and tuberculosis. The
BAL fluid is cultured and most biopsies are stained (sil-
ver staining, Gomori) to exclude the presence of fungal
infection. IgA, IgG and IgG antibodies against Candida
and Aspergillus are determined.
Indications for treatment at the clinic are stage II and III
with worsening of pulmonary symptoms, including cough
and/or shortness of breath or chest pain, and one or more
of the following criteria: deteriorating lung function with a
fall in total lung capacity of 10 percent or more, a fall in
forced vital capacity in one second (FEV1)o f1 5p e r c e n to r
more, a decrease in diffusing capacity of 20 percent or
more, decreased gas exchange at rest or with exercise, pro-
gressive radiologic changes or development of signs of pul-
monary hypertension. All patients with extra-pulmonary
sarcoidosis are treated. Treatment is not given to patients
with stage I, II or III who are asymptomatic.
The protocol for treatment at the clinic is methylpred-
nisolone 0.5 mg/kg ideal body weight every day after
breakfast during the first for four weeks and then 0.25
mg/kg alternative day therapy during one year.
Subjects for the study were recruited from the sarcoi-
dosis patients during the period September 2005 till
June 2010. During this period there were 207 patients
(24 stage I, none treated, 142 stage II, 66 treated, 34
stage III, 28 treated, and 6 stage IV, all treated). The
subjects were chosen on an ad hoc basis when they
came to follow-up at the outpatients’ care.
We recruited 8 patients with stage I, 71 patients with
stage II, 27 patients with stage III and one with stage
IV. Extra pulmonary manifestations were present in 27.
They were divided into three groups. One comprised
subjects with newly diagnosed sarcoidosis and currently
undergoing treatment based on the clinical criteria
described above. The second group was subjects diag-
nosed with mild sarcoidosis of all stages, not receiving
treatment or who had been successfully treated more
than two years earlier and had no evidence of active dis-
ease. The third group comprised subjects who failed to
respond to treatment for more than one year or had a
relapse of the disease after termination of treatment
(stage II and III except for one subjects with stage IV).
There was only five smokers in the group.
Controls were members of the staff and other contacts
who were healthy, non-smoking and without respiratory
symptoms and without family members with respiratory
disease. The study was approved by the Ethical Commit-
tee at the University Medical Centre, Ljubljana (198/05/
04) and informed consent was obtained.
Determinations were made of pulmonary diffusion
capacity (DLCO). serum angiotensin converting enzyme
(sACE), chitotriosidase (CTO), and total IgE, using stan-
dard laboratory methods. These measurements were not
performed among the controls.
Background data for the different groups are shown in
Table 1.
T h eg r o u p sw e r er e l a t i v e l yc o m p a r a b l ea l t h o u g ht h e
mean age was slightly lower in the group under treat-
ment and the proportion of females was slightly higher
in the group with no recurrence. The CTO value was
slightly higher in the group under treatment than in the
o t h e rg r o u p s( N S ) .T h eI g Ev a l u ew a sh i g h e ri nt h e
Table 1 Characteristics of study subjects
Group Control Sarcoidosis
Parameter <1 year no
recurrence
recurrence
n3 0 5 5 2 5 2 7
Mean age years 46,4
(2.7)
43.2 (1.6) 49.4 (2.6) 47.7 (2.0)
Females % 50.0 55.6 61.9 44.8
DLCO% - 89 (2) 87 (4) 86 (4)
BAL CD4
+/CD8
+ - 7.6 (0.9) 5.6 (0.9) 4.6 (0.8)
sACE μKat/L - 0.43 (0.03) 0.44 (0.04) 0.38 (0.05)
CTO nmol/h/mL - 632 (86) 523 (91) 513 (97)
Total IgE mg/mL - 98 (26) 125 (50) 313 (197)
Extrapulmonary
manifestations
-2 5 8 1 2
Mean and SEM.
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(NS). Extra pulmonary manifestations were slightly
more frequent in the group < 1 year than in the other
groups (NS).
Air sampling
The participants were supplied with a portable pump
equipped with filter holders preloaded with cellulose
acetate filters (PCM Cassettes with mixed Cellulose
Esters Filter, 25 mm, 0.8 μmp o r es i z e ,Z e f o nI n t e r n a -
tional, Inc., Ocala, FL, USA). The subjects turned on the
pump and sampling was performed during about four
hours. The windows and doors to the room were closed
several hours prior to the sampling. The exact volume
sampled was read from a volume meter attached to the
pump and was usually about 2.5 m
3.
Enzyme analysis
For the enzyme analysis one mL of a fluorogenic
enzyme substrate (4-methylumbelliferyl N-acetyl-beta-
D-glucosaminide, Mycometer A/S, Copenhagen, Den-
mark) was added to the filter and incubated for around
30 minutes - the exact time being set by the room tem-
perature. Thereafter 2 mL of an alkaline buffer (the
developer) was added to the filter. The liquid in the fil-
ter holder was sucked out through the filter and col-
lected in a cuvette. The fluorescence of this fluid was
read in a fluorometer (Picofluor, Turner Designs, Sun-
nyvale, CA, USA) and the fluorescence value for a con-
trol filter was deducted from the sample value. One
count is equal to 2.3 ng Apergillus oryzae NAHA. To
avoid random scatter, the values read in the fluorometer
were divided by 10 and given as a round figure to
express the NAHA enzyme activity in units (U/m
3).
The reproducibility of the sampling is very high. With
two filters samples taken in parallel in 25 different
rooms, the R
2 was 0.956 with ANOVA f 504.2, p <
0.001. For samples taken on two occasions a few weeks
apart in 26 rooms, the R
2 was 0.796 with ANOVA f
93.42, p < 0.001. Repeated readings of the same sample
on the fluorometer showed very small variations in the
order of a few units.
Statistical analysis
Differences between groups were evaluated for statistical
significance using the Mann-Whitney and the chi
2 tests.
Relationships were calculated using Spearman’st e s t .A
p-value of 0.05 was considered significant.
Results
The activities of NAHA in the different groups are
shown in Table 2.
Subjects under treatment or with recurrence had sig-
nificantly higher values than controls and those who
were treated and had no recurrence (p < 0.001, Mann-
Whitney).
T h eN A H Av a l u e sw e r eh i g h l ys k e w e da n dt h ev a l u e s
from the whole material (controls and sarcoidosis) were
thus divided into those below or above the second quar-
tile (14 NAHA U/m
3). Table 3 shows the number of
controls and cases of sarcoidosis in the low and high
exposure groups.
The difference in distribution between controls and
subjects under treatment less than a year was significant
(p < 0.001) as well as that of controls vs recurrence (p <
0.001, chi
2 test). For those with no recurrence, there
was no difference to controls.
Discussion
The major result from the study is that high activities of
an airborne enzyme indicating fungal cell mass were
found significantly more often in the homes of subjects
with ongoing or recurrent sarcoidosis.
There are some limitations in the study. The measure-
ments were made on one occasion only. For a complete
environmental assessment, measurements should also
have been made at the workplace or in other environ-
ments where the subject spent considerable time. On
the other hand experience from a previous study [11]
suggests that mould levels in a certain room vary rela-
tively little within a year, particularly in buildings with
high levels of moulds. Provided that windows and doors
in the room where measurements were made are closed
prior to the sampling, the values reflect the exposure of
the inhabitants, irrespectively of outdoor conditions.
In spite of these shortcomings considerable differences
were found between the level of airborne enzyme in
homes of persons with sarcoidosis and control subjects.
There was a larger proportion of subjects with high
Table 2 NAHA U/m
3 in rooms of subjects in different
groups of sarcoidosis. Mean and SEM
Group control < one year no recurrence recurrence
n3 0 5 5 2 5 2 7
NAHA 10.0 (1.1) 33.6 (5.0) 12.0 (1.8) 39.9 (7.6)
Table 3 Presence of low and high activities of NAHA
(below or above the 2
nd quartile, 14 NAHA U/m
3)i n
homes of controls and patients without and with
recurrence of sarcoidosis
Group n low high
Controls 30 25 5
Sarcoidosis
- treatment < 1 year 55 20 35
- no recurrence 25 16 9
- recurrence 27 9 18
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recurrent sarcoidosis. From an exposure point of view
this is logical, as a continuous exposure to a causative
agent would represent a risk for recurrence, as com-
pared to an exposure that occurred during a limited
time period and was no longer present when the disease
had been treated. The reason why subjects with a his-
tory of disease but no recurrence had low values could
be due to cleaning of the home, remediation of building
related humidity problems or moving to another loca-
tion, No systematic evaluation of these possibilities was
made in this study,
The analysis of airborne samples comprised the deter-
mination of NAHA as a measure of fungal biomass.
Measurements of fungal cell agents are more precise
than ocular inspection to detect fungi [12]. Previous stu-
dies have reported that NAHA represents fungal bio-
mass both in the growth and stationary phase [13-15].
Significant correlations between NAHA and total spore
counts were found in air samples and in dust generated
from biomass in a biofuel plant [16,17]. Strong correla-
tions were found between fungal biomass (gravimetric
weight) and NAHA in fungal species grown on nutrient
agar and between ergosterol and NAHA activity on
mould contaminated gypsum boards [9]. A linear corre-
lation between NAHA and Aspergillus niger biomass
has been reported [18].
NAHA is produced by a range of organisms including
bacteria, fungi, protozoa, and mammalian cells and is
thus not specific for fungi. On the other hand when the
fungi grow indoors such in humid conditions, there is
no reason to believe that other sources of NAHA such
as pollen or mammalian cells would also multiply. A
previous study has demonstrated that the sensitivity and
specificity for detection of buildings with fungi are very
high [19] and the possible confounding sources of
NAHA did not play an important role. Although bac-
teria are generally present in environments with fungal
growth, their cell wall agents such as endotoxin elicit
other kinds of immunological responses than the granu-
lomatous inflammation induced by fungal components
such as b-glucan.
None of the cases of sarcoidosis investigated had any
signs of fungal infection as evidenced by low titres
against common fungi and negative cultures of lung
biopsies or lung lavage. This suggests that, if fungi con-
tribute to the development of sarcoidosis, the effect
would be mediated by other mechanisms than infection.
T h e r ea r es e v e r a lf u n g a lc e l lc o m p o n e n t sw h i c hm a y
influence the innate immune system. For one of these -
b-glucan - information is available both from experi-
mental and field studies [8]. At low doses, similar to
those present in the environment, the major initial effect
is an immune suppression and a Th2 deviated lympho-
cyte response which may deviate to a Th1 driven
response with repeated exposures [20]. This effect
would be present even if the fungal cell is dead as b-glu-
can is known to remain in tissue several weeks after the
disintegration of the fungal cell itself [8].
The proportion of patients with high activities of
NAHA in their homes was larger in the group with
recurrent disease. This suggests that they were continu-
ously exposed to fungi. Cleaning of fungal growth at
home might thus be a measure to prevent the recur-
rence of sarcoidosis.
The indoor environment comprises exposure to a vari-
ety of agents some of which have the potential to cause
irritation in the airways. Even if the primary agent stu-
died here was fungal cell mass, it cannot be excluded
that agents such as cooking fuels or environmental
tobacco smoke might influence the exposure outcome
and hence the risk of disease. Nutritional factors are an
example of another important environmental influence.
Antioxidant status has also been associated with sarcoi-
dosis although it is unclear if it is a consequence of the
disease [21].
Conclusion
Measurements of the enzyme NAHA as a marker for
fungal biomass demonstrated significantly higher
activities in homes of subjects with sarcoidosis, parti-
cularly among those with recurrent disease. This sug-
gests that exposure to fungi contributes to the
pathology of the disease. Evaluations of fungal expo-
sure in the environment of patients with sarcoidosis
should be considered, particularly for those with
recurrent sarcoidosis. Routine examination of sarcoi-
dosis patients should include information on potential
fungal exposure at home or at the workplace and
cleaning actions could be suggested.
Abbreviations
NAHA: N-acetylhexosaminidase; CTO: chitotriosidase; sACE; serum
angiotensin converting enzyme; BAL: brochoalveolar lavage; FEV1; forced
expiratory volume in one second; NS: non significant
Acknowledgements
Funding was received from the University Medical Centre, Ljubljana and
BioFact Environmental Health Research Centre, Sweden
Author details
1Clinic of Respiratory Diseases and Allergy, University Medical Centre,
Ljubljana, Slovenia.
2BioFact Environmental Health Research Centre, Lerum,
Sweden.
Authors’ contributions
M.T., B.S., and M.H. were responsible for the clinical issues. R.R. was
responsible for the NAHA measurements and the manuscript structure. All
authors contributed to the data analysis and have read and approved the
final manuscript.
Terčelj et al. Environmental Health 2011, 10:8
http://www.ehjournal.net/content/10/1/8
Page 4 of 5Competing interests
The authors declare that they have no competing interests.
Received: 5 August 2010 Accepted: 20 January 2011
Published: 20 January 2011
References
1. duBois RM, Goh N, McGrath D, Cullinan P: Is there a role for
microorganisms in the pathogenesis of sarcoidosis? J Int Med 2003,
253:4-17.
2. Kucera GP, Rybicki BA, Kirkey KL, Coon SW, Major ML, Maliarik MJ,
Iannuzzi MC: Occupational risk factors for sarcoidosis in African-American
siblings. Chest 2003, 123:1527-1535.
3. Newman LS, Rose CS, Bresnitz EA, the ACCESS research group: A case-
control etiological study of sarcoidosis - environmental and
occupational risk factors. Am J Respir Crit Care Med 2004, 170:1324-1330.
4. Laney AS, Cragin LA, Blevins LZ, Sumner AD, Cox-Ganser JM, Kreiss K,
Moffatt SG, Lohff CJ: Sarcoidosis, asthma, and asthma-like symptoms
among occupants of a historically water-damaged office building. Indoor
Air 2009, 19:83-90.
5. Kern DG, Neill MA, Wrenn DS, Varone JC: Investigation of a unique time-
space cluster of sarcoidosis in firefighters. Am Rev Resp Dis 1993,
148:974-980.
6. Prezant DJ, Dhala A, Goldstein A, Janus D, Ortiz F, Aldrich TK, Kelly KJ: The
incidence, prevalence, and severity of sarcoidosis in New York
firefighters. Chest 1999, 116:1183-1193.
7. Terčelj M, Salobir B, Rylander R: Microbial antigen treatment in sarcoidosis
- A new paradigm? Medical Hypothesis 2008, 70:831-834.
8. Rylander R: Organic dust induced pulmonary disease - the role of mould
derived β-glucan. Ann Agr Env Med 2010, 17:9-13.
9. Reeslev M, Miller M, Nielsen KF: Quantifying mold biomass on gypsum
board: comparison of ergosterol and beta-N-acetlyhexosaminidase as
mold biomass parameters. Appl Env Microbiol 2003, 69:3996-3998.
10. Statement on sarcoidosis: Joint statement of the American Thoracic
Society (ATS), the European Respiratory Society (ERS) and the World
Association of Sarcoidosis and other Granulomatous Disorders (WASOG)
adopted by the ATS Board of Directors and by the ERS Executive
Committee, February 1999. Am J Respir Crit Care Med 1999, 160:736-755.
11. Heinrich J, Hoscher B, Douwes J, Richter K, Koch A, Bischof W, Fa B,
Kinne RW, Wichmann HE: Reproducibility of allergen, endotoxin and
fungi measurement in the indoor environment. J Exposure Annals Env
Epidemiol 2003, 13:152-160.
12. Reponen T, Singh U, Schaffer C, Vesper S, Johansson E, Adhikari A,
Grinshpun SA, Indugula R, Ryan P, Levin L, LeMasters G: Visually observed
mold and moldy odor versus quantitatively measured microbial
exposure in homes. Sci Tot Env 2010.
13. Rast DM, Horsch M, Furter R, Gooday CW: A complex chinolytic system in
exponentially growing mycelium of Mucor rouxii. J Gen Microbiol 1991,
137:2797-2810.
14. Cirano JU, Peberdy JF: Effect of carbon source on chitobiase production
by Trichoderma harzianum. Mycol Res 1993, 97:45-48.
15. Miller M, Palojärvi A, Rangger A, Reeslev M, Kjöller A: The use of
fluorogenic substrates to measure fungal presence and activity in soil.
Appl. Environ. Microbiol 1998, 64:613-617.
16. Madsen AM: NAGase activity in airborne biomass dust and relationship
between NAGase concentration and fungal spores. Aerobiologica 2003,
9:97-105.
17. Madsen AM, Schlünssen V, Olsen T, Sigsgaard T, Avci H: Airborne fungal
and bacterial components in PM1 dust from biofuel plants. Ann Occ Hyg
2009, 53:749-757.
18. Konkol N, McNamara CJ, Mitchell R: Fluorometric detection and
estimation of fungal biomass on cultural heritage materials. J Microbiol
Meth 2010, 80:178-182.
19. Rylander R, Reeslev M, Hulander T: Airborne enzyme measurements to
detect indoor mould exposure. J. Environ. Monit 2010, 12:2161-2164.
20. Bosco A, McKenna KL, Devitt CJ, Firth MJ, Sly PD, Holt PG: Identification of
novel Th2-associated genes in T memory responses to allergens.
J Immunol 2006, 76:4766-4777.
21. Boots AW, Drent M, Swennen ELR, Moonen HJJ, Bast A, Haenen GRMM:
Antioxidant status associated with inflammation in sarcoidosis: A
potential role for antioxidants. Resp Med 2009, 103:364-372.
doi:10.1186/1476-069X-10-8
Cite this article as: Terčelj et al.: Fungal exposure in homes of patients
with sarcoidosis - an environmental exposure study. Environmental
Health 2011 10:8.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Terčelj et al. Environmental Health 2011, 10:8
http://www.ehjournal.net/content/10/1/8
Page 5 of 5